Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety ...

Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

Alicia Morgans, MD, MPH, discusses a potentially practice-changing abstract from the 2025 American Society of Clinical ...

The trial met one of its dual primary endpoints in the intent-to-treat population and will proceed to the planned final analysis for the second primary endpoint of overall survival in patients without ...

ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple ...

Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing ...

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free ...

The cure to cancer may not be hidden in some drug or chemical but within our own body. A team of Chinese researchers recently ...

Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...

New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in ...

OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel ...